Evidence-Based Oncology | February 2017

Evidence-Based Oncology

Immunotherapy treatments are not without side effects. What do patients and their families need to know so they are more aware?
A note from the editor-in-chief.
Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.
An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Community oncologists will be at the forefront of using immunotherapies and will need to be strong advocates for greater information and affordability of therapies.
The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?
Patients, caregivers, and providers need education on immunotherapy treatment, support in patient-provider communications as well as support in mitigating the financial impact of immunotherapy treatment.
An oncologist provides insight on his experience with using CAR-T therapy in the clinic and his prediction for the future of this revolutionary treatment.
AJMCtv® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.

More issues

Compendia
COPD Compendium
Diabetes Compendium
GI Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$vacMongoViewPlus$